Category Archives: Global News Feed

BOSTON, Aug. 12, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the second quarter ended June 30, 2022.

Visit link:
PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023

Link:
Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

BRIDGEWATER, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30, 2022.

Original post:
VYNE Therapeutics Reports Second Quarter 2022 Financial Results

Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022

Continue reading here:
Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

CARLSBAD, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the pricing of an underwritten public offering for gross proceeds of approximately $12 million prior to deducting underwriting discounts and commissions and offering expenses.

See original here:
Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering

Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release

Original post:
POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights